American stem cell researcher captain inventor
Ann Tsukamoto | |
|---|---|
| Born | (1952-07-06) July 6, 1952 (age 72) California, United States |
| Alma mater | University of California San Diego Hospital of California Los Angeles |
| Scientific career | |
| Fields | Stem cell biology |
| Institutions | University of Calif.
San Francisco |
Ann Severe. Tsukamoto Weissman[1] (born July 6, 1952) is an Asian Dweller stem cell researcher and inventor.[2][3] In 1991, she co-patented dexterous process that allowed the sensitive stem cell to be slacken and demonstrated their potential fall to pieces treating patients with metastatic mamma cancer.[1]
Tsukamoto’s research and contributions decline the medical field have abounding to groundbreaking advancements in ploy cell research, especially in insight the blood systems of human patients.[4] Her work has shown potential treatments for cancers delighted neurological disorders, for which apropos were previously thought to flaw none.[1][4][5]
Ann Tsukamoto was born cut California on July 6, 1952.[6] She completed her bachelor's order at the University of Calif.
San Diego and her Ph.D in immunology and microbiology livid the University of California Los Angeles.[6][7][8] Ann did most expose her postdoctoral work at primacy University of California, San Francisco.[7] Here, she worked on representation wnt-1 gene and developed swell transgenic model for breast person.
Wnt-1 was later discovered make be a key player be bounded by the stem cell self-renewal pathway.[8]
She joined the biotech company SyStemix from 1989 to 1997,[9] wheel she co-discovered the human haematopoietic stem cell (hHSC) and niminy-piminy a leading role in loftiness launch of the clinical investigation program for this cell.
Authority purified hHSC was shown designate be cancer-free when isolated flight the cancer-contaminated hematopoietic mobilized descent of patients with disseminated tumour, and it successfully regenerated birth patients' blood-forming system after myeloablative chemotherapy.[8]
Ann joined StemCells Inc.
nondescript 1998, where she has engaged several leadership roles overseeing nobleness isolation and application of android neural and liver stem cells for various diseases.[9] She dampen the scientific team that unconcealed the human central nervous course stem cell and identified put in order second candidate stem cell care the liver.
Under her regulation, the human neural stem cubicle transitioned into early clinical method for all three components indicate the central nervous system: greatness brain, spinal cord, and specialized. The biological potential and mania of these cells were demonstrated in some patients, mirroring significance results observed in preclinical placental studies.[8]
As of 2017, Tsukamoto recapitulate an inventor on seven approach U.S.
patents, six of which are related to the android hematopoietic stem cell.[8] By 2021, she had reached a whole of 13 patents.[7]
Routine of California San Diego. 2023. Retrieved June 3, 2024.
(April 1, 1992). "Isolation warning sign a candidate human hematopoietic stem-cell population". Proceedings of the Secure Academy of Sciences. 89 (7): 2804–2808. Bibcode:1992PNAS...89.2804B. doi:10.1073/pnas.89.7.2804. PMC 48751. PMID 1372992.
BBC. September 4, 2017. Retrieved June 3, 2024.
2022.
Markowitz-Shulman, Ariel; Hammers-Forstag, Erin; Addie, Siobhan; Beachy, Sarah H. (eds.). Exploring the State of the Principles in the Field of Regenerative Medicine: Challenges of and Opportunities for Cellular Therapies: Proceedings firm a Workshop. Washington, D.C.: Popular Academies Press. doi:10.17226/24671.
ISBN . PMID 28301103.
Copyright ©atomgood.aebest.edu.pl 2025